








































A study of zinc protoporphyrin-polymer 
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DMEM  ?????????????  Dulbecco's modified Eagle medium 
DMF   N,N-??????????  N,N-dimethylformamide 
DMSO  ??????????  dimethylsulfoxide 
EPR  enhanced permeability and retention 
ESR  ???????  electron spin resonance 
HA   ??????  hyaluronic acid 
HPLC  ?????????????  high performance liquid chromatography 
IC50  ??????  50% inhibitory concentration 
PBS  ??????????  phosphate-buffered saline 
PDT  ??????  photodynamic therapy 
PEG  ????????????  poly(ethylene glycol) 
PHPMA poly(N-(2-hydroxypropyl)methacrylamide) 
PP   ????????? IX  protoporphyrin IX 
PPED  bis(ethylenediamino)protoporphyrin 
ROS  ?????  reactive oxygen species 
SDS  ??????????? sodium dodecylsulfate 
SMA  poly(styrene-co-maleic acid)   
THF  ?????????  tetrahydrofuran 
TLC  ???????????  thin layer chromatography 
ZnPP  ???????????  zinc protoporphyrin 


































Figure 1. Schematic drawing of enhanced permeability and retention effect and photodynamic 
therapy 
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Figure 2. Chemical structures of zinc protoporphyrin (ZnPP), zinc bis(ethylenediamino) 














? ? ????????? IX?PP?100 mg ?0.178 mmol????????????THF?20 
mL??????????????????????10?????????????








? ? ???? PPED?HPLC?????????????Asahipak GF-310??? 7.5×300 
mm???????????????? 10ppm ?????????????????
????3?/??????7????????? 15????? 0.8 mL/min?????? 415 
nm????PPED??????? 12?????? PP???????????? 5.1
?????????? 
? ? TLC????? ??????/?????=9/1?v/v??????? 60F254?MERCK?
 
6 
? Rf?????????PP? Rf?? 0?????????????????? PP?
Rf?? 0.9?PPED? Rf?? 0??????????? 
 
??????????????????????????????????????????????? ???
? ? PPED 100 mg?0.154 mmol????????????DMSO?100 mL??????
PPED ? 10 ???????????????????????????????
60 °C?2??????????????????????10?????????DMSO




? ? Poly?styrene-co-maleic anhydride??SMA?100 mg? ZnPPED 20 mg?0.028 mmol??
DMF 10 mL???????????ZnPPED? 10???????????????
WSC???????? 60 °C? 24?????????????????? 10???
??????????????????????????????????????
??????????? 0.2 M ????????? 40 mL??????60 °C? 24
??????????? ZnPPED ??????????????????????




? ? UV-2075 UV/????????????????????? LC-2000Plus series 
?????????????????Asahipak GF-310 HQ??? 7.5×300 mm???????










? ? SMA-ZnPP ? DMSO ???????????pH 7.4?????????????
F-4500?????????????????????? 420 nm????? 550−700 nm
??????????????????SMA-ZnPP????Tween 20??????0.2?




? ? HeLa ?????????????? 10%??????????????????
????????????????????DMEM??????? 37 °C?5% CO2??
????????96 well???????????? HeLa??? 3,000 cells/well???
????????24 ?????????????? SMA-ZnPP?????????
???SMA-ZnPP???? 24???????????????? 420 nm?11.1 W/m2?
???? 15 ???????????? 24 ?????????? well ? 0.5 mg/mL





? ? 6???? ddY?????? 35−40 g??????????????2×106 cells ??
?????? S-180?????????????????????? 10 mm????




?????100 mg?? 1 mL? DMSO????????12,000 g? 10??????





? ? ??????? 10 mm ????????????????S-180???SMA-ZnPP 
?15 mg-ZnPP/kg???????????????????? IVIS Lumina XR?Caliper 








? ? ??????Figure 2 ???????PPED ???????????? ZnPPED
????????? SMA ??????????????????????????






Figure 3. Typical chromatograms of ZnPPED (A) and SMA-ZnPP (B) 
? ? SMA-ZnPP conjugate was analyzed by high performance size exclusion chromatography. 
Column: Asahipak GF-310 HQ (i.d. 7.5 × 300 mm), mobile phase: DMF, flow rate: 0.5 
mL/min, detection: absorbance at 415 nm. 
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????????????? ZnPPED????????? 6.2 ???????Figure 3 
B?????SMA-ZnPP???? ZnPPED??????????????? ZnPPED?
????????????SMA-ZnPP?????? 55%?????????????
? ZnPP????????? SMA-ZnPP?? ZnPP??? 15 wt%????????PBS
???? 20 mg/mL??????????SMA-ZnPP??????????? 
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Figure 4. Particle size of SMA-ZnPP conjugate in PBS. 
? ? Hydrodynamic particle size of SMA-ZnPP conjugate was measured by dynamic light 
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??????????????? Tween 20??????? SMA-ZnPP??????
?????????????Tween 20??????????ZnPP????????
?????????????Figure 5 B??????????????????????











Figure 5. Fluorescence spectra of SMA-ZnPP conjugate under various conditions.  
? ? Fluorescence intensity of SMA-ZnPP in distilled water was smaller than that in DMSO 
(A).  SMA-ZnPP (0.01 mg/mL) was dissolved in PBS, and its fluorescence intensity in the 


























































Figure 5. Fluorescence spectra of SMA-ZnPP conjugate under various conditions.  
 
???????? ???????
? ? ???????? SMA-ZnPP???????????????HeLa?????
? SMA-ZnPP? ZnPP??????????????????? ZnPP??????
????????????????????????? SMA-ZnPP????????
??????Figure 6?? 





























































µg-ZnPP/mL ????????ZnPP ? IC50?? 5 ?g/mL ???????SMA-ZnPP
? IC50?? 6?? 1?????ZnPP??? SMA-ZnPP?????????????
?????SMA-ZnPP???????????SMA-ZnPP? IC50?? 12 ?g-ZnPP/mL
?????????????????? 3??????? 
 
   
Figure 6. In vitro cytotoxicity of SMA-ZnPP conjugate with or without light irradiation in 
HeLa cells. 
? ? HeLa cells seeded on a 96 well plate at 3,000 cells per well.  At 24 h later, HeLa cells 
were treated with SMA-ZnPP or ZnPP.  After another 24 h, HeLa cells were treated with or 
without light irradiation (blue fluorescent light 420 nm, 1.0 J/cm2), which were incubated for 




? ? S-180???????????? SMA-ZnPP?????IVIS Lumina-XR????










Figure 7. In vivo tumor imaging (A) and body distribution of SMA-ZnPP conjugate (B) after 
i.v. injection in tumor-bearing mice.  
? ? SMA-ZnPP (15 mg-ZnPP/kg) was injected into S-180 tumor bearing mice.  (A) At 
indicated times, fluorescence images were taken by an IVIS Lumina-XR.  (B) At 24 h later, 
mice were dissected, which each organ was collected.  SMA-ZnPP was extracted from one 
organ, and was quantified by fluorescence spectrometer.  Excitation wavelength: 420 nm.  
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Figure 7. In vivo tumor imaging (A) and body distribution of SMA-ZnPP conjugate (B) after 
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? ? ZnPP ? SMA ???????????????in vitro ???????????
??????????????????????in vivo?????????????
?????????????????????26, 38, 39??ZnPP? SMA??????

















































2,4,6-Trinitrobenzenesulfonic acid sodium salt dehydrate?TNBS??DMEM?????????
RPMI 1640?????? G-??????????×100??0.25% trypsin-EDTA????
????????? 100,000???????????????? 
? ? ???? 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazoliumbromide?MTT??
2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt 
?WST-1???????????????????????????????? 3,000?





? ? PP 500 mg? DMSO 200 mL?????????????? 15 g????70 °C
? 2 ?????????????????????? 400 µL????????PP















? ? HA 100 mg?????? 3,000?? DMT-MM 180 mg? DMSO 10 mL??????
????????????? ZnPPED 8 mg? DMSO 2 mL???? HA??????
?????????? 4 ????????????????????????? 10
????????????HA-ZnPP?????????????? ZnPPED? HA?







? ? DMSO??????HA-ZnPP?0.5 mg/mL?????ZnPPED?0.05 mg/mL??10 µL
?????0.1 M ????????????pH 9.8?10 µL?TNBS?0.5 mg/mL?10 µL?





? ? ZnPPED ??? HA-ZnPP ???????????????????PV-2080??
?????????UV-2075???????????Asahipak GF-310 HQ??? 7.5×300 mm??
?????415 nm?????10ppm??????????? DMSO?3?/??????7?
???????0.8 mL/min ????????????????????? HA-ZnPP
??????0.15 M KCl?????????pH 5.4????????10 mg/mL?????
????????HA-ZnPP???10 mg/mL????? 37 °C????????????
???????Prominence HPLC ????????????????????????




? ? HA-ZnPP? PBS??????0.5 mg/mL??????????? 0.45 µm????









? TEMPD?????????? JES-FA100 ???????????? 
 
?????
? ? HeLa ????????????????? DMEM????????????
S-180??????????? RPMI?Roswell Park Memorial Institute?1640??????
?????????? 10%??????????????????? G-??????




? ? HeLa??? 24 well plate? 2×105 cells/well??????????24 ?????
??ZnPP??? HA-ZnPP????? 10 µg-ZnPP/mL???????????????
?????????????PBS? 2???????1% SDS??????????
???????????????????? 60 W? 20?????????????
??? DMSO?????HA-ZnPP??? ZnPP??????????????? 420 
nm????? 500−700 nm???????? HA-ZnPP??? ZnPP????????
??????????????????BCA protein assay kit???????????
??????????????????????????????????????




? ? HeLa???? S-180??? 96 well plate ? 1 well??? 3,000 cells?????24 
???????HA-ZnPP??? ZnPP????????24??? 48 ???????
?????50 W/m2?? 5???????48 ????WST-1????MTT?????
 
23 
???????????????????WST-1?? 4?????????? 420 nm
??????MTT?? 3?????????? 570 nm??????????????
????MTT ??????????MTT ???????????100 µL ? DMSO
??????????????????????????????????????
?? HA-ZnPP????0.15 M KCl??? 0.1 M ??????pH 5.4????????
???????3 mg/mL???????????HA-ZnPP ?????HA-ZnPP ?? 3 











? ? ???? 10 mm ??????????????????HA-ZnPP?ZnPP 15 
mg-ZnPP/kg??????????????? 24 ??? 48 ???????????
??????????????????????????????????????
??????? 100 mg???? DMSO 0.9 mL?????????????????
?????????15,000 rpm?????? 3,000 rpm?? 15???????????
???????????THF ?????????????????????????






? ? ???????? 5 mm ???????????????? HA-ZnPP ????
ZnPP?????????HA-ZnPP??? ZnPP?????15 mg-ZnPP/kg?????










? ? ZnPP?????????????????????????? Soret?????
?? 405 nm?? 422.5 nm??????Q?????? 2????????????
???? 
? ? ZnPPED ??????????????????????TLC?????????
???Figure 9??ZnPP ????????????????????????? ZnPP
?????????????????????? ZnPP?????????????
?????? ZnPPED ????????????????? Rf???? 0 ????
?Figure 9?? 
? ? ???????? HA-ZnPP??????HA-ZnPP????? 20 wt%?????
????? 415 nm??????????????? ZnPP?????? HA-ZnPP?
? ZnPP ????????????HA-ZnPP ?? ZnPP ???? 10 wt%?????
HA-ZnPP ??????????????????????????? ZnPPED ??
??????????????Figure 10 A??????ZnPPED? HA-ZnPP? HPLC?
?????????ZnPPED?????? 5.1??????? HA-ZnPP?? 7.4??
?????????Figure 10 B?????? HA-ZnPP ?????????????
ZnPPED?????????????????? 





?????????HA-ZnPP ??? ZnPPED ?????????????????





? ? PBS ?????? HA-ZnPP ???????????????????????
? 129.8 ± 49.1 nm?????Figure 11?????HA-ZnPP?????????????
??? 3,000? HA??????? 3.1 ± 1.2 nm????? 
 
 
Figure 9. Thin-layer chromatographic analyses of ZnPP, activated ZnPP and ZnPPED in the 
synthesis of ZnPPED. 









Figure 10. Picture of ethanol washings during the purification of HA-ZnPP after conjugation 
of ZnPPED to HA (A) and typical HPLC chromatograms of ZnPPED (top of B) and 
HA-ZnPP (bottom of B).  
? ? HA-ZnPP conjugate was analyzed by high performance size exclusion chromatography. 
Column: Asahipak GF-310 HQ (i.d. 7.5 × 300 mm), mobile phase: mixture of DMSO (3) and 























Figure 11. Particle size of HA (A) and HA-ZnPP (B) in PBS. 
? ? Hydrodynamic particle sizes of HA and HA-ZnPP conjugate were measured by dynamic 
light scattering, showing mean particle size of 3.1 and 129.8 nm, respectively. 
? ?
Particle size (nm)?








































? ? HA-ZnPP????????????????? 350−700 nm??????????
?????? 420 nm????? 500−700 nm?????????HA-ZnPP??? ZnPP
???????????? 422.5 nm??????????????????????
???? 400 nm??????????SDS??????? HA-ZnPP??? ZnPP?



























Figure 12. UV-Vis absorption spectra of HA-ZnPP (A) and ZnPP (B) in various media. 
? ? HA-ZnPP or ZnPP was dissolved in various media indicated in the panels, and their 
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Figure 13. Fluorescence spectra of HA-ZnPP (A) and ZnPP (B) in various media. 
? ? HA-ZnPP or ZnPP was dissolved in the indicated solutions in the panels, and their 
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Figure 14. Fluorescent spectra of HA-ZnPP in PBS containing lecithin (A) and urea (B). 
? ? HA-ZnPP was dissolved in PBS, and was mixed with lecithin (A) and urea (B). 
Fluorescence spectra of HA-ZnPP in each was measured by a fluorescence spectrometer.   























































































Figure 15. 1O2 generation from HA-ZnPP upon light irradiation. 
? ? 1O2 generation from HA-ZnPP and ZnPP dissolved in (A) PBS and PBS containing (B) 
0.1% lecithin, (C) 1% SDS or (D) DMF.  HA-ZnPP or ZnPP solutions were irradiated with a 
xenon lamp at 400–700 nm (20 mW/cm2) for indicated time period.  1O2 generated in the 
solutions was captured by 4-oxo-TEMP, and the resulting 4-oxo-TEMPO was detected by 























Figure 16. HPLC chromatograms of HA-ZnPP treated with hyaluronidase. 
? ? HA-ZnPP was allowed reacting with hyaluronidase in acetate buffer (pH 5.4) containing 
0.15 M KCl at 37 °C, and the resulting materials were analyzed by HPLC.  Column: 
Asahipak SB804 HQ (i.d. 8.0 × 300 mm), mobile phase: 0.1 M sodium phosphate buffer (pH 














































Figure 17. Fluorescence spectra of HA-ZnPP treated with hyaluronidase. 
? ? HA-ZnPP (0.5 mg/mL) was dissolved in acetate buffer (pH 5.4) containing 0.15 M KCl, 
and was allowed reacting with 0.5 mg/mL hyaluronidase at 37 °C.  Fluorescent spectra of 
HA-ZnPP were measured by a fluorescence spectrometer at the indicated time after mixing 
with the enzyme.  Excitation wavelength: 420 nm.  
 
??????? ??????????
? ? HeLa?????????????????????????? HA-ZnPP?? ZnPP
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Figure 18. Cellular uptake of HA-ZnPP into HeLa cells.   
? ? Hela cells seeded on 1.88 cm2 dishes were treated with ZnPP or HA-ZnPP in the absence 
or presence of HA for indicated time period.  Intracellular drug amount was determined by 
fluorescence spectrometry, and normalized by the cellular protein amount.  Data were mean 
± standard deviation (n = 6). 
 























































Figure 19. Cytotoxicity of HA-ZnPP to HeLa (A and C) and S-180 cells (B). 
? ? HeLa (A) and S-180 (B) cells seeded on 96-well plates were treated with HA-ZnPP.  
HeLa cells (C) were also treated with HA-ZnPP pretreated with hyaluronidase.  At 24 h light 
irradiation, cells were incubated another 48 h.  Cell viability was determined by MTT or 

















without light irradiation 


















without light irradiation 








? ? ??????????? HA-ZnPP???? ZnPP??????????????
??????? 24 ??????ZnPP?????????????????????
????????????????HA-ZnPP???????? ZnPP????????
???????????????????????? 48 ???? HA-ZnPP????
????????????EPR ??????? HA-ZnPP ????????????
?????Figure 20?? 
? ? ??????? 5 mm? S-180????????HA-ZnPP??????????
?????????????????????HA-ZnPP????HA-ZnPP?? + light
????ZnPP????ZnPP?? + light?????????light?????????
HA-ZnPP?? + light???????????? 31????????????????
?????????????????????ZnPP?? + light?????????
??????????????????????????????????????
????????? 56?70??????????????HA-ZnPP?? + light???
???? 100%??????????HA-ZnPP????ZnPP?????40%????

















without light irradiation 








Figure 20. Body distribution of HA-ZnPP in S-180 tumor-bearing mice at 24 (A) and 48 (B) h 
after the ZnPP or HA-ZnPP administration.  
? ? S-180 tumor-bearing mice were received ZnPP or HA-ZnPP at 15 mg-ZnPP/kg via the 
tail vein.  At 24 and 48 h after the ZnPP or HA-ZnPP administration, mice were sacrificed 
and selected organs were collected after transcardial perfusion with saline.  The amounts of 
















































































































standard deviation (n = 6). 
 
Figure 21. Antitumor effect of HA-ZnPP in S-180 tumor-bearing mice.   
? ? S-180 tumor-bearing mice were treated with 15 mg-ZnPP/kg of ZnPP or HA-ZnPP 
(black arrows) followed by with or without light irradiation (white arrows).  Tumor volumes 
were measured as described in Materials and Methods.  Data were mean + standard 









































Figure 22. Representative images of mouse treated without drug (A), and mouse treated with 






? ? ??????? HA-ZnPP??????? 3,000? HA? ZnPPED???????
??????????????????? 30,000 ? HA ???????? HA-ZnPP
????????????????ZnPPED??? HA?????????????
?????????????????? 3,000? HA??????????? ZnPPED
??????????HA 100 mg???? ZnPPED 10 mg???????? ZnPP??
???????????????? HA-ZnPP ??????????? HA-ZnPP ??
????????????????????????? ZnPPED? HA??????
???????? HA-ZnPP?? ZnPP???? 10 wt%?????????HA-ZnPP
???? 3,000? HA 1??? ZnPP 1?????????????????????
??14.0 wt%????????????????????? HA-ZnPP ???????
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